Galena Biopharma Inc (GALE) Price Target Lowered to $6.00 at Roth Capital


The brokerage presently has a "buy" rating on the biotechnology company's stock. Roth Capital's price objective indicates a potential upside of 308.16% from the company's current price.



from Biotech News